Intellia Therapeutics, Inc. (NTLA)
Automate Your Wheel Strategy on NTLA
With Tiblio's Option Bot, you can configure your own wheel strategy including NTLA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NTLA
- Rev/Share 0.4403
- Book/Share 7.5354
- PB 0.9502
- Debt/Equity 0.1529
- CurrentRatio 4.8972
- ROIC -0.5931
- MktCap 741654280.0
- FreeCF/Share -3.6827
- PFCF -1.9458
- PE -1.4091
- Debt/Assets 0.1209
- DivYield 0
- ROE -0.5867
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NTLA | Wolfe Research | Peer Perform | Outperform | -- | $21 | April 21, 2025 |
| Initiation | NTLA | H.C. Wainwright | -- | Buy | -- | $30 | March 5, 2025 |
| Downgrade | NTLA | Goldman | Neutral | Sell | -- | $9 | Feb. 28, 2025 |
| Downgrade | NTLA | JP Morgan | Overweight | Neutral | $45 | $13 | Feb. 28, 2025 |
| Downgrade | NTLA | Morgan Stanley | Overweight | Equal Weight | $56 | $11 | Jan. 27, 2025 |
News
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) - April 14, 2025 Deadline to Join - Contact Levi & Korsinsky
Published: April 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=141502&wire=1 or contact Joseph E. Levi, Esq.
Read More
NTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: April 07, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , April 7, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ: NTLA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between July 30, 2024 and January 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2025.
Read More
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia Therapeutics, Inc. (NTLA) Shareholders
Published: April 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=141092&wire=1 or contact Joseph E. Levi, Esq.
Read More
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: April 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=140953&wire=1 or contact Joseph E. Levi, Esq.
Read More
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Published: April 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Intellia securities between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period").
Read More
Intellia Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=140786&wire=1 or contact Joseph E. Levi, Esq.
Read More
NTLA Deadline: NTLA Investors with Losses in Excess of $100K Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit
Published: April 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 3, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. So what: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA).
Read More
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class Action Lawsuit and an Upcoming Deadline
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=140741&wire=1 or contact Joseph E. Levi, Esq.
Read More
NTLA DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - NTLA
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ:NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2024 lead plaintiff deadline. SO WHAT: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Intellia securities between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period").
Read More
Intellia Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 14, 2025 to Discuss Your Rights - NTLA
Published: April 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
Published: April 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=140484&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
Published: April 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=140240&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, A TOP-RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA
Published: April 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2024 lead plaintiff deadline.
Read More
April 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NTLA
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=140205&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA
Published: April 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Levi & Korsinsky Reminds Intellia Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Published: March 31, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=140024&wire=1 or contact Joseph E. Levi, Esq.
Read More
Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NTLA
Published: March 31, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=139997&wire=1 or contact Joseph E. Levi, Esq.
Read More
Intellia Focuses on Pipeline Development Amid Stiff Competition
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Studies on NTLA's gene-edited therapy, nex-z, are progressing well while other pipelines are picking up pace. Stiff competition in the target market is a woe.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA
Published: March 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=139553&wire=1 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA
Published: March 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ:NTLA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=139215&wire=1 or contact Joseph E. Levi, Esq.
Read More
Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/intellia-therapeutics-inc-lawsuit-submission-form?prid=139202&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ:NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2024 lead plaintiff deadline. SO WHAT: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class Action Lawsuit and an Upcoming Deadline
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.
Read More
NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Intellia securities between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period").
Read More
The Gross Law Firm Reminds Intellia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - NTLA
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
About Intellia Therapeutics, Inc. (NTLA)
- IPO Date 2016-05-06
- Website https://www.intelliatx.com
- Industry Biotechnology
- CEO Dr. John M. Leonard M.D.
- Employees 403